# US 10,869,885 B2 · Tumor lysate loaded particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,869,885 B2
- Document ID: US10869885B2
- Status: Granted
- Kind: B2
- Application number: 15/864,496
- Filed: 2018-01-08
- Published: 2018-08-02
- Granted: 2020-12-22
- Earliest claimed: 2012-09-06
- Assignees: Orbis Health Solutions LLC
- Applicants: Orbis Health Solutions LLC
- Inventors: Thomas E. Wagner
- Web page: https://patentgrep.com/patent/US10869885B2

## CPC

- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}
- A61P 35/00: Antineoplastic agents
- A61K 2039/572: {cytotoxic response}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/55: Lung
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Dendritic cells containing tumor lysate loaded particles are prepared. The dendritic cells present tumor antigens to elicit the Major Histocompatibility Complex class I pathway and can be used as a vaccine to treat cancer, including ocular melanoma.

## Claims

### Claim 1

A method for producing a tumor lysate loaded particle comprising:
(i) contacting a suspension of yeast cell wall particles (YCWPs) with a tumor lysate, wherein contacting the suspension comprises:
(a) incubating the suspension of YCWPs with the tumor lysate,
(b) freeze-drying the suspension of YCWPs, and
(c) washing the YCWPs, wherein steps (a)-(b) are repeated at least once with a step of adding water into the yeast cell particle before step (a) is repeated; and
(ii) freeze-drying the suspension of YCWPs and the tumor lysate to produce a tumor lysate loaded particle.

### Claim 2 (depends on 1)

The method of claim 1, the tumor lysate is a lysate of a cancer selected from the group consisting of breast cancer, small cell lung cancer, non-small cell lung cancer, glioma, medulloblastoma, neuroblastoma, Wilms tumors, rhabdomyosarcoma, osteosarcoma, liver cancer, pancreatic cancer, melanoma, prostate cancer and ocular melanoma.

### Claim 3 (depends on 1)

A vaccine comprising a tumor lysate loaded particle produced by the method of claim 1.

### Claim 4 (depends on 3)

The vaccine of claim 3 further comprising a CpG oligonucleotide.

### Claim 5 (depends on 3)

The vaccine of claim 3 further comprising a tetanus toxoid MHC class II-binding p30 peptide.

### Claim 6 (depends on 3)

The vaccine of claim 3 further comprising a dendritic cell.

### Claim 7 (depends on 6)

The vaccine of claim 6, wherein the tumor lysate loaded particle is phagocytosed by the dendritic cell.

### Claim 8 (depends on 3)

A method for treating cancer comprising administering the vaccine of claim 3 to a patient in need thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cancer is selected from the group consisting of breast cancer, small cell lung cancer, non-small cell lung cancer, glioma, medulloblastoma, neuroblastoma, Wilms tumors, rhabdomyosarcoma, osteosarcoma, liver cancer, pancreatic cancer, melanoma, prostate cancer and ocular melanoma.